VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, presented data highlighting the proposed mechanism of action (“MOA”) of its Phase 3 investigational drug candidate, PH94B nasal spray, in a poster session at … Continue reading “NetworkNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Presents Data Regarding Drug Candidate for Replacement of Addictive Benzodiazepines”
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that its Chief Executive Officer, Shawn Singh, will participate in two investor conferences in March. For the Maxim Group and M-Vest’s Inaugural … Continue reading “NetworkNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming March Investor Conferences”
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced promising preclinical data for its PH10 drug candidate. The data demonstrate that the potential mechanism of action of PH10, VistaGen’s Phase 2 investigational pherine nasal spray with potential as a rapid-onset, stand-alone treatment … Continue reading “NetworkNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Preclinical Data Demonstrating Differentiated Mechanism of Action of PH10 from Benzodiazepines”
VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications that go beyond the standard of care for anxiety and depression. A recent article discussing this reads, “Depression and anxiety are at the forefront of concern for VistaGen, a company working to develop innovative product candidates to address these … Continue reading “NetworkNewsBreaks – VistaGen Therapeutics Inc.’s (NASDAQ: VTGN) Pipeline Holds Potential to Go Beyond Standard of Care for Anxiety, Depression”
American Psychiatric Association poll reveals 62% of respondents have anxiety about COVID-19 Recent FDA Drug Safety Communication requires updated Boxed Warning for benzodiazepines commonly used to treat anxiety disorders VTGN is committed to developing and commercializing PH94B, a first-in-class pherine nasal spray with potential to go beyond the current standard of care for acute treatment … Continue reading “VistaGen Therapeutics Inc. (NASDAQ: VTGN) Committed to Developing New Generation Alternatives to Current Standard of Care for Anxiety Disorders”
Mental health experts note growing concern over impact of COVID-19 on nation’s mental health Compounding stress could have serious health, social consequences VTGN offers new hope to those dealing with depression disorders A new survey from the American Psychological Association (“APA”) shines a spotlight on the growing concern about the impact of the global pandemic … Continue reading “VistaGen Therapeutics Inc. (NASDAQ: VTGN) Committed to Developing New Generation of Medicines with Potential to Treat Rising Mental Health Challenges from Depression”
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has reported its financial numbers for its fiscal 2021 third quarter, ending Dec. 21, 2020. Highlights of the report are the company’s strengthened balance … Continue reading “NetworkNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 Financial Report, Clinical Studies Update”
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has announced plans to begin a Phase 3 clinical trial in Q2 2021. The clinical trial will evaluate PH94B (“PH94B”), a neuroactive nasal spray … Continue reading “NetworkNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preparing Phase 3 Trial to Evaluate Neuroactive Nasal Spray Treatment for SAD”
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced its receipt of notice from The Nasdaq Stock Market on Jan. 5, 2021, that VistaGen has regained compliance with the minimum bid price requirement. The requirement is under Nasdaq Listing Rule 5550(a)(2) (the … Continue reading “NetworkNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Regains Full Compliance with Nasdaq Listing Requirements”
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that VistaGen Vice President, Translational Medicine Dr. Louis Monti and VistaGen CNS Clinical and Regulatory Advisory Board Member Dr. Michael Liebowitz authored an article published in CNS Spectrums, a Cambridge University Press journal. … Continue reading “NetworkNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Publication Detailing Its Investigational Neuropharmaceuticals for Anxiety and Depression Disorders”
